Product Description
Cefotiam is a third-generation, semi-synthetic, beta-lactam cephalosporin antibiotic with antibacterial activity. Cefotiam binds to penicillin-binding proteins (PBPs), transpeptidases that are responsible for crosslinking of peptidoglycan. By preventing crosslinking of peptidoglycan, cell wall integrity is lost and cell wall synthesis is halted. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Cefotiam)
Mechanisms of Action: Cell Wall Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: China | Egypt | France | Germany | Indonesia | Ireland | Korea | Peru | Philippines | Taiwan | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Beijing Boshi Antai Technology Development Co., Ltd.
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Respiratory Tract Infections|Urinary Tract Infections
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20150519 |
CTR20150519 | P3 |
Recruiting |
Respiratory Tract Infections|Urinary Tract Infections |
None |
2025-04-29 |
Patient Enrollment|Treatments |
Recent News Events
Date |
Type |
Title |
|---|